A NanoLuc Luciferase Reporter Pseudorabies Virus for Live Imaging and Quantification of Viral Infection

Yalin Wang†, Hongxia Wu†, Bing Wang†, Hansong Qi†, Zhao Jin‡, Hua-Ji Qiu* and Yuan Sun*†

†State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China; ‡College of Life Science and Agriculture Forestry, Qiqihar University, Qiqihar, China

Pseudorabies (PR), also known as Aujeszky's disease, is an acute infectious disease of pigs, resulting in significant economic losses to the pig industry in many countries. Since 2011, PR outbreaks have occurred in many Bartha-K61-vaccinated pig farms in China. The emerging pseudorabies virus (PRV) variants possess higher pathogenicity in pigs and mice than the strains isolated before. Here, a recombinant PRV (rPRVTJ-NLuc) stably expressing the NanoLuc (NLuc) luciferase fusion with the red fluorescent protein (DsRed) was constructed to trace viral replication and spread in mice. Moreover, both DsRed and NLuc luciferases were stably expressed in the infected cells, and there was no significant difference between wild-type and recombinant viruses in both growth kinetics and pathogenicity. Seven-week-old BALB/c mice were infected with 10³ 50% tissue culture infective dose rPRVTJ-NLuc and subjected to daily imaging. The mice infected with rPRVTJ-NLuc displayed robust bioluminescence that started 4 days postinfection (dpi), bioluminescence signal increased over time, peaked at 5 dpi, remained detectable for at least 6 dpi, and disappeared at 7 dpi, meanwhile, the increased flux accompanied by the spread of the virus from the injection site to the superior respiratory tract. However, the signal was also observed in the spinal cord, trigeminal ganglion, and partial region of the brain from separated tissues, not in living mice. Our results depicted a new approach to rapidly access the replication and pathogenicity of emerging PRVs in mice.

Keywords: pseudorabies virus, NanoLuc luciferase, in vivo, image, mouse

INTRODUCTION

Pseudorabies (PR), a devastating disease in the pig industry worldwide, is characterized by neurological signs, respiratory signs, high morbidity, and mortality of piglets, whereas older pigs mostly exhibit respiratory and reproductive diseases (1). Pseudorabies virus (PRV) is the causative agent of the acute infectious PR in swine. Due to control efforts and strict implementation of national eradication programs, PR has been eradicated from domestic pigs in North America and several European countries. However, the disease is sporadic in many other countries, including China (2). In late 2011, there was a PR outbreak on many large pig farms where piglets were vaccinated with Bartha-K61 vaccine, and quickly the disease occurred in six provinces in China. The mortality rate of infected piglets was from 10 to 50%, which caused great economic loss (3). Moreover, about 57.8% of 5,033 serum samples isolated during the year 2013 to 2016 were positive for PRV gE antibody, so PRV variant strains were still prevalent in China (4). The PRV variants...
shared 97.1–99.9% nucleotide (nt) and 96.6–99.5% amino acid (aa) homology with PRV reference strains, and they belonged to different clades (3). Mutation of glycoproteins C and D of PRV variants led to the escape from Bartha-K61 vaccine-induced immunity (5), so gE/gI/TK-deleted PRV variant strains as a substitute for Bartha-K61 vaccine were used in China to control PR at present. Except for the immunogenicity change, the pathogenicity of PRV variant strains enhanced compared with the classic strain in both pigs and mice; however, it is not clear about the mechanism of enhanced pathogenicity to its hosts (6).

Fluorescent proteins or luciferase-tagged viruses have been widely used in the researches of viral infection and replication mechanisms (7–9). Reporters that have luminescence properties possess greater advantages in some areas of virological research due to higher signal–noise ratio and sensitivity compared with fluorescent proteins (10). Many studies have demonstrated several significant advantages of investigating viral pathogenesis with imaging. Bioluminescence imaging (BLI) is a powerful alternative, enabling rapid measurements of viral load and tissue distribution (11–14). Spatial and temporal progression of infection can be quantified, and viral replication and dissemination in the animals can be identified (15). The traditional approaches for viral pathogenicity studies require the killing of animals at diverse time points for the determination of viral titers in excised organs and tissues, whereas BLI does not (16). In addition, BLI can identify unexpected sites or patterns of viral infection that could be missed if organs are not collected or if entire organs are not analyzed for viral titers (14). This approach has been exploited in multiple viruses, including dengue virus, herpes simplex virus type 1, Sindbis virus, influenza virus, and Sendai virus (12, 14, 15, 17, 18).

Here, we generated a recombinant PRV (rPRVTJ-NLuc) stably expressing the engineered luciferase variant NanoLuc and red fluorescent protein DsRed. NLuc is a 19-kDa luciferase engineered from the deep-sea shrimp that possesses ∼150-fold greater specific activity than firefly luciferase (19, 20). The reporter gene of NLuc that fused with DsRed was inserted immediately downstream of the US9 gene. The replication dynamics of the recombinant PRV is similar to PRVTJ. Moreover, rPRVTJ-NLuc possesses pathogenicity and lethality indistinguishable from those of PRVTJ in mice. These results demonstrated that the recombinant PRV was not attenuated both in vitro and in vivo. Furthermore, we reported the visualization of PRV infection in mice. These data suggest that imaging of the recombinant PRV can be used to rapidly assess the replication and pathogenicity characteristics of emerging PRVs; these will provide a reference for control PR caused by PRV variants.

**MATERIALS AND METHODS**

**Cells, Viruses, and Plasmids**

The PRVTJ strain (GenBank accession number: KJ789182.1) was isolated from a pig farm outbreak in Tianjin of China, propagated in PK-15 cells, and stored at −70°C. PK-15 and Vero cells were maintained at 37°C with 5% carbon dioxide (CO2) in Dulbecco’s modified Eagle medium (DMEM, Thermo-Fisher Scientific, Carlsbad, CA, United States) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, United States). Both cell lines were obtained from the China Center for Type Culture Collection (Wuhan, China).

The left and right homologous arms (flanking the PRV US9 gene, named as L and R) of transfer vector were amplified by using primer pairs P1S/P1R and P2S/P2R. The NLuc gene was amplified with primers P4S/P4R from pNL2.1 vector (Promega, Madison, WI) and inserted into the DsRed expressing vector pDsRed2-C1 (Clontech, USA) through EcoRI site firstly, and then, the inserted fragment together with CMV promoter and polyA terminator was amplified by PCR with primers P3S/P3R. The resulting L arm, R arm, and exogenous gene were amplified; 100–300 ng of DNA template was used per reaction for overlap PCR; the long DNA segment was cloned into blunt T-vector and sequenced to make sure to get the target sequence. Then, the large DNA segment was amplified, purified, and ligated into the pOK12 vector (Novagen, USA) between the KpnI and Xhol DNA restriction enzyme sites to get the recombinant vector pOK-NLuc-DsRed using T4 DNA ligase (Thermo Scientific, USA).

**Transfection, Virus Rescue, and Plaque Purification**

The genomic DNA of PRVTJ was extracted using the phenol–chloroform extraction method. Vero cells seeded in six-well culture plates were co-transfected with 1-µg pOK-DsRed-NLuc plasmid and 1-µg genomic DNA of PRVTJ strain using 4 µl of the X-tremeGENE HP DNA transfection reagent (Roche, USA) according to the manufacturer’s instructions. The first generation recombinant viruses were collected at 2–3 days after transfection.

For plaque purification, PK-15 cells seeded in six-well culture plates were infected with 10-fold serially diluted rPRVTJ-NLuc strain from 10−1 to 10−5 for 1 h at 37°C in a 5% CO2 incubator; then, the supernatant was removed; cells were covered with 1% agarose gel and incubated for 2 days till clear cytopathic effect with red fluorescent of DsRed protein formed. Marked plaques were picked by pushing the 200-µl tip through the overlay agarose, and this was diluted in 1-ml DMEM for the next generation of plaque purification. A total of five generations of plaque purification were performed to obtain the purified recombinant viruses.

**Virus Titration and One-Step Growth Assay**

The viral titer was determined by 50% cell culture infectious dose (TCID50). In brief, PK-15 cells seeded in 96-well plates were infected with 10-fold serially diluted viruses (10−2 to 10−8) and cultured at 37°C in a 5% CO2 incubator for 72 h. The number of wells with red fluorescence was counted, and the viral titers were calculated using the Reed & Muench method (21).

One-step growth kinetic of rPRVTJ-NLuc was compared with PRVTJ. The monolayers of PK-15 cells in the 24-well cell culture plates were infected with rPRVTJ-NLuc or PRVTJ at a multiplicity of infection (MOI) of 10 for 1 h at 37°C. Extracellular viruses were inactivated by low-PH treatment (22); supernatant and cells were harvested at different time points (12-h interval) till 60-h post-infection; three repeat samples were harvested at each time point and stored at −80°C. After the sample
returned to room temperate, the cellular debris was removed by centrifugation, and the TCID\textsubscript{50} of supernatant was detected on PK-15 cells. Average values and standard deviations of the three independent experiments were calculated.

**Polymerase Chain Reaction**

Genomic DNA was extracted from PK-15 cells infected with rPRVTJ-NLuc or PRVTJ at an MOI of 1 for 12 h using the Tissue DNA Kit (Omega). The primer pairs P5S/P5R, P6S/P6R, and P7S/P7R that were complementary to the glycoprotein B (gB), glyco-protein I (gI), NLuc luciferase, and DsRed fluorescent protein genes are listed in Table 1. The amplification was conducted in a total volume of 50 µl (gB), glyco-protein I (gI), NLuc luciferase, and DsRed fluorescent protein genes are listed in Table 1.

**Western Blot Assay**

The monolayers of PK-15 cells in the 6-well cell culture plates were infected with rPRVTJ-NLuc, rPRVTJ-DsRed, or PRVTJ at an MOI of 1 for 12 h using the Polymerase Chain Reaction system (Promega), and luminescence was detected with TD-20/20 luminometer (Turner Designs).

**Luciferase Assay**

PK-15 cells seeded in 96-well cell culture plates were infected with 10-fold serially diluted rPRVTJ-NLuc strain from 10\textsuperscript{-2} to 10\textsuperscript{-5} at 37°C in a 5% CO\textsubscript{2} incubator for 12 h. The supernatants were removed, and cells were washed once with PBS before cell culture lysis buffer (Promega) was added. Cell lysates were assayed for luminescence activity with the Nano-Glo Assay System (Promega), and luminescence was detected with TD-20/20 luminometer (Turner Designs).

**Infection of Mice With rPRVTJ-NLuc or PRVTJ and Tissue Collection**

All the mice were handled according to the Guide for the Care and Use of Laboratory Animals of Harbin Veterinary Research Institute (HVRI), Chinese Academy of Agricultural Sciences, China. Two mice experiments were made in this work: one for the pathogen detection and another one for the live imaging test. For the pathogen detection, 35 6-week-old specific-pathogen-free (SPF) female BALB/c mice were used in this study. The mice were randomly allocated into seven groups, five mice in one box. Mice of groups 1, 2, and 3 were injected intramuscularly (i.m.) with 10\textsuperscript{3}, 10\textsuperscript{4}, or 10\textsuperscript{5} TCID\textsubscript{50} of PRV TJ strain in 100-µl DMEM, respectively. Groups 4, 5, and 6 were injected i.m. with 10\textsuperscript{4}, 10\textsuperscript{3}, or 10\textsuperscript{2} TCID\textsubscript{50} rPRVTJ-NLuc in 100 µl of DMEM, respectively. Group 7 was the mock-inoculations (medium only) in parallel. Mice were scored daily for symptoms of PRV infection using the following three-point system adapted from the protocol previously described (23). All the mice in the infected and control groups were anesthetized by CO\textsubscript{2} before euthanasia, using the broken-neck method at 7 dpi. Fresh tissues from the heart, liver, spleen, lungs, kidneys, brain, spinal cord, and trigeminal ganglion of mice were collected, one part of the samples was fixed in buffered formalin for hematoxylin and eosin assay, and 100 mg of another part of the samples was stored at −80°C for DNA extraction. Total DNA was extracted using Tissue DNA Kit (Omega) according to the manufacturer's instructions and stored at −20°C for quantitative PCR (qPCR) analysis.

**Real-Time PCR (Quantitative PCR)**

Real-time PCR (qPCR) was used to quantitatively analyze the viral loading in the brain, heart, liver, spleen, lung, kidney, spinal cord, and trigeminal ganglion using the reported method of Meng (24). Briefly, viral genomic DNA was amplified using the gI gene-specific primer PRV-FI (5'-GCC GAG TAC CTC TGC C-3'), PRV-R1 (5'-CGA GAC GAA CAG CGG CCG-3'), and TaqMan probes HEX-PRV-Var (HEX-5'-CGG GTT CGA GAA AATGCTC-3'), each sample was done in triplicate, deionized water as the negative control.
Pathology and Histopathology
The samples were fixed in buffered formalin and embedded in paraffin wax. Tissue sections were prepared and stained with hematoxylin and eosin assay for histopathological examinations.

In vivo Imaging
For the live imaging test, a total of 30 7-week-old SPF female BALB/c mice were separated into six groups for PRV infection, five mice in each group, and another five mice were injected with DMEM as control. Mice were infected with $10^5$ TCID$_{50}$ rPRVTJ-NLuc or PRVTJ by three different inoculation routes: inoculated intraperitoneally (i.p.) (in the lower abdominal region), i.m. (in the right hind leg muscles), or subcutaneously (s.c.) (in the back of the neck). In vivo imaging was performed from 3 to 7 dpi with a 24-h interval using the BLI system of the LB 983 NightOWL II (Berthold, Germany) equipped with a cooled slow-scan CCD camera and driven by the IndiGo™ software (version 2.0.5.0, Berthold). At each time point, five mice in each group per day were anesthetized with isoflurane (Burbank, CA 91502, USA) and injected with 100 µl of Nano-Glo reagent (Promega) (diluted 1:20 in PBS) via the tail vein. Flux measurements were acquired from regions of interest automatically gated to the signal contours, keeping the mice at 37°C during the whole progress. All the mice in the infected and control groups were anesthetized by CO$_2$ before euthanasia, using the broken-neck method after imaging the experiment. All data in composite images utilized the same scale.

Statistics
Data represent means ± standard deviations ($n \geq 3$). The comparison between groups was performed by a Student's $t$-test with a two-tailed analysis. Data are considered significant when $P < 0.05$.

RESULTS

Generation and Characterization of the Recombinant Pseudorabies Virus Expressing NanoLuc
PRV genome is characterized by two unique regions ($U_L$ and $U_3$), and the $U_3$ region flanked by internal and terminal repeat sequences. As reported, the noncoding interval sequence between $U_3$9 open reading frame and $U_5$2 open reading frame in the $U_3$ regions is long enough to tolerate large exogenous genes (25). A single cassette of NLuc fused with the DsRed was designed immediately downstream of the US9 gene of the PRV TJ genome (Figure 1A). The transfer vector pOK-DsRed-NLuc with two 1.5-kb homologous arms and PRVTJ genomic DNA were co-transfected into Vero cells, and the first generation of recombinant virus was collected at 2–3 days after transfection when the cytopathic effect formed on the Vero cells. We obtained the purified virus through five rounds of plaque purification. The plaque morphology of rPRVTJ-NLuc had no significant difference from its parental virus (Figure 1B). We confirmed that the chimeric NLuc cassette was inserted immediately into the downstream of the US9 gene of PRVTJ using corresponding specific primers by PCR and sequencing. The stability of the reporter genes, NLuc, and DsRed, was also tested by following amplification and serial passages in PK-15 cells (P1 to P20) (Figure 1D). These results indicated there were gB and gI genes in the genome backbone of the recombinant PRV, which was the same as its parental strain. Also, the reporter genes could exist in the backbone simultaneously and stably, which were detected in the following passages. The expression of DsRed and viral protein was checked by Western blot using antibody target DsRed, gD, and gB proteins. The same bands of gB and gD presented in the samples of rPRVTJ-NLuc, rPRVTJ-DsRed, and PRVTJ infected groups; meanwhile, the band of DsRed protein of rPRVTJ-NLuc was larger than rPRVTJ-DsRed due to NLuc fused with it (Figure 1E).

We compared the growth kinetics of rPRVTJ-NLuc with the parental strain PRVTJ in PK-15 cells. The titers of rPRVTJ-NLuc in the culture supernatant had no significant difference with those of PRVTJ during 60-h post-infection (hpi), suggesting that the growth properties of rPRVTJ-NLuc were similar to those of PRVTJ (Figure 1C). To examine the relationship between NLuc expression level and rPRVTJ-NLuc infection, the correlation between the input of rPRVTJ-NLuc and NLuc luciferase activities was evaluated. PK-15 cells were infected with rPRVTJ-NLuc with different amounts of input virus: ranging from $10^0$ to $10^5$ TCID$_{50}$/ml. NLuc luciferase activities were measured at 12 hpi. The activities of luciferase in supernatants increased over time, and the yield of luminescent flux was directly correlated with viral titers ($R^2 = 0.96$) (Figures 1F,G). The result demonstrated that the luminescent flux could represent the titer of the recombinant PRV in the infected cell.

rPRVTJ-NLuc Possesses Similar Pathogenicity to PRVTJ in Mice
To monitor symptoms and organ lesions preferably, mice were infected with $10^5$, $10^3$, or $10^2$ TCID$_{50}$ PRVTJ or rPRVTJ-NLuc via the i.m. route. Clinical signs, including pruritus, anxiety, rolling, and scratching of the injection site, were recorded every day throughout the experiment. The mice infected with $10^4$ TCID$_{50}$ viruses (groups 1 and 4) began showing clinical signs around 72 hpi. The mice infected with $10^3$ TCID$_{50}$ viruses (groups 2 and 5) showed similar symptoms but delayed. The mice infected with $10^2$ TCID$_{50}$ doses of viruses (groups 3 and 6) showed barely clinical symptoms. No difference was observed in the clinical performance of mice injected with the same dose of PRVTJ and rPRVTJ-NLuc (Table 2). Mice infected with $10^4$, $10^3$, or $10^2$ TCID$_{50}$ of PRVTJ or rPRVTJ-NLuc lost body weight and led to die in a dose-dependent manner (Figures 2A, B). The mice infected with the same dose of PRVTJ or rPRVTJ-NLuc exhibited similar weight loss and mortality. These results demonstrated that the clinical symptoms of the recombinant PRV did not change after the insertion of the reporter genes.

Next, we determined whether the fatal clinical outcome and distinct pathology of the mice that were infected could be attributed to viral replication in specific tissues. Various tissues, as listed earlier, were collected after euthanasia for qPCR analysis to determine PRV DNA loads. As shown in Figure 2C, the virus could be detected in the brain, kidney, spinal cord, and
FIGURE 1 | Generation and characterization of the recombinant PRV expressing NLuc luciferase. (A) Schematic representation of NLuc and DsRed cassette inserting immediately downstream of the US9 gene. (B) Recombinant PRV can form plaques and express DsRed in the PRV-infected PK-15 cells. Original magnification ×200; bar, 400 µm. (C) One-step growth curve of rPRVTJ-NLuc. (D) Identify of rPRVTJ-NLuc by PCR. Left panel, verification of the gB, gI gene in the genome of rPRVTJ-NLuc, and PRVTJ. Middle panel and right panel, identification of the NLuc and DsRed reporter genes in different passages in infected PK-15 cells, respectively. (E) Expression of NLuc fused with DsRed in rPRVTJ-NLuc-infected cells was detected by Western blot, the DsRed expression of rPRVTJ-DsRed as control; moreover, viral protein gD and gB of all PRV strains were also detected using anti-gD and anti-gB monoclonal antibodies, normal cells as mock. (F) Average luciferase activity of the recombinant PRV in the PK-15 cells at 12 hpi with defined amounts of input virus (n = 5). (G) Correlation curve between titers of virus and luciferase activities using Pearson's correlation coefficient.
Extended scoring systems for clinical signs. Clinical signs were recorded every day, incorporating 4 parameters such as: pruritus, anxiety, rolling and scratching of the injection site, each parameter was scored from 0 = no clinical symptom; 1 = mild symptoms, such as subtle neurological symptoms, unitidy hair and minor depression; 2 = common symptoms, such as pruritus, rolling and scratching the injection site; 3 = severe symptoms, such as severe pruritus, self-mutilate even acute death. The results are expressed as mean value ± s.d. (n = 5) of total value of 4 parameters. -, death.

| Virus       | Dose (TCID<sub>50</sub>) | Days post-infection |
|-------------|--------------------------|---------------------|
| PRVTJ       | 10<sup>4</sup>           | 0 0 11 ± 1          |
|             |                          | 1 2 3 4 5 6 7       |
| rPRVTJ-NLuc | 10<sup>4</sup>           | 0 0 9.75 ± 0.96     |
|             |                          | 1 2 3 4 5 6 7       |
| DMEM        | 100 µl                   | 0 0 0 0             |

In summary, there is no difference in clinical symptoms, replication, spread, and histopathology between the mice infected with rPRVTJ-NLuc and its parental virus. So, the insertion of NLuc into the PRV genome was stable, and the recombinant rPRVTJ-NLuc could be used as a tool to study the pathogenicity of PRVTJ.

**In vivo Imaging of rPRVTJ-NLuc Showed the Viral Replication and Dissemination in Mice**

BLI has been exploited in multiple viruses, including dengue virus, herpes simplex virus type 1, Sindbis virus, and Sendai virus (15, 17, 18). Here, we used rPRVTJ-NLuc to visualize PRV replication and spread in mice. Seven-week-old BALB/c mice were infected with 10<sup>3</sup> TCID<sub>50</sub> rPRVTJ-NLuc and subjected to daily imaging (Figure 3A). Bioluminescence was detected as early as 4 dpi at the site of injection. Luminescent flux increased throughout infection and peaked on day 6, then waning. The enhanced signal could be detected when rPRVTJ-NLuc spread from the injection site to the superior respiratory tract.

To get better *in vivo* images, mice were infected with rPRVTJ-NLuc and PRVTJ by three different inoculation routes. Mice were infected with 10<sup>3</sup> TCID<sub>50</sub> viruses *via* inoculated i.p. (in the lower abdominal region), i.m. (in the right hind leg muscles), or s.c. (in the back of the neck). As expected, mice infected with rPRVTJ-NLuc displayed robust bioluminescence, which started 4 dpi, increased over time, peaked at 5 dpi, remained detectable for at least 6 dpi (Figure 3B), and disappeared at 7 dpi when the virus was cleared after a sublethal infection. All mice inoculated viruses *via* i.m. route showed severe clinical symptoms at 4 dpi, pruritus, rolling, and scratching the injection site, and all died at 5 dpi. This result illustrated that the i.m. route may more easily cause peracute death. Real-time imaging of the same mouse over time from each group revealed viral load and dissemination from the injection site to the spinal cord and CNS.

To confirm the local tissues scattering bioluminescence, selected mice were killed, and their organs were immediately removed. Isolated organs were placed in a furimazine bath, and BLI was undertaken. Signals of the spinal cord, trigeminal ganglion, and a partial region of the brain were observed (Figure 3C). There were robust bioluminescence signals in the spinal cord, brain, and trigeminal ganglion based on the flux of each excised organs (Figure 3C). These results were consistent with the viral distribution in diverse organs of mice infected with rPRVTJ-NLuc, which possessed the ability to visualize a pathogenic infection in mice.

**DISCUSSION**

Since late 2011, there were PR-like outbreaks in a large number of vaccinated pig farms in China (26). It is found that the PRV variant strain and the classical strain belong to different phylogenetic branches. In our previous study, the epidemic strain exhibited enhanced pathogenicity in mice and pigs (6). The reemergence of the PRV outbreak resulted in huge economic losses to the pig industry in China, so the ability that can quickly assess the pathogenicity of the epidemic strains and its susceptibility to antiviral interventions was urgently required.
FIGURE 2 | Pathogenicity of recombinant PRV compared with PRVTJ in mice. Six-week-old SPF BALB/c mice were injected intramuscularly with $10^4$, $10^3$, or $10^2$ TCID$_{50}$ of rPRVTJ-NLuc or PRVTJ. (A) Average body weights of the infected mice ($n = 5$) at 7 dpi. (B) Survival rates of mice infected indicated a dose of viruses. (C) Viral DNA copies in different tissue. All the mock-infected and PRV-infected mice were euthanized and subjected to dissection at a moribund stage or 7 dpi. Specific tissues were collected from the mice infected with $10^4$ or $10^3$ TCID$_{50}$ rPRVTJ-NLuc or PRVTJ and tested by qPCR. (D) Histopathological changes in diverse organs of mice infected with rPRVTJ-NLuc or PRVTJ; bar = 100 µm.
FIGURE 3 | In vivo imaging of a PRV reporter in a mouse model. (A) Noninvasive imaging detected robust bioluminescence in the mice infected with 10^3 TCID₅₀ rPRVTJ-NLuc or PRVTJ and analyzed for bioluminescence at indicated time points. (B) Longitudinal in vivo imaging of rPRVTJ-NLuc in mice showed viral replication and dissemination. Mice were inoculated intraperitoneally, subcutaneously, or intramuscularly with 10^3 TCID₅₀ rPRVTJ-NLuc and PRVTJ. In vivo imaging was performed every day from 3 dpi at the indicated time points. (C) In situ localization of NLuc luciferase activity in the excised organs of mice infected with the recombinant PRV. Seven-week-old SPF BALB/c mice were i.p. inoculated with 10^3 TCID₅₀ rPRVTJ-NLuc and killed at 4 dpi. Organs were dissected out and placed separately in a substrate bath. Bioluminescent images were taken 10 min later, and the representative image shows the distribution of luminescent activity in the specimen (right). Quantification of the luminescent activity in the excised organs. After an exposure time of 30 s, a region of interest was manually defined, and the luminescent activity was calculated by the IndiGo™ software (left). All the images of the mice shown in the figure were one representation of five repeats.
In this study, we constructed a recombinant PRV stably expressing the NLuc luciferase fusion with red fluorescent protein DsRed. The double-labeled strategy is convenient for in vitro screening of the recombinant virus with DsRed and the in vivo imaging with NLuc luciferase. There was no difference in the growth properties of rPRVTJ-NLuc and PRVTJ. Moreover, the recombinant rPRVTJ-NLuc possessed pathogenicity and lethality in mice indistinguishable from those of PRVTJ.

The infection of PRV in rodents routinely shows severe clinical manifestations, including pruritus, frantically clawing, and biting of the inoculation site, even self-mutilation and acute death eventually (27). To monitor the symptoms and organ lesions preferably, we infected mice with a lower dosage, 10^4, 10^3, or 10^2 TCID_{50} PRVTJ, or rPRVTJ-NLuc via i.m. route. Similar symptoms were found in mice infected with 10^4 or 10^3 TCID_{50} PRVTJ or rPRVTJ-NLuc; the groups of 10^2 TCID_{50} viruses and control were no symptomatic; all these results were the same as Brittle reported. Previous studies demonstrated that mice infected with PRV-Becker develop severe pruritus in the inoculation site, resulting in self-mutilation and peracute death with no detectable behavioral CNS pathology and no obvious pathological changes in the brain. Merely, the peripheral nervous system (dorsal root ganglia and trigeminal ganglia) has significant pathological changes (2, 28). Nevertheless, we detected the replication of the virus and inflammatory pathological changes in CNS tissue and kidneys of mice; maybe, these explained why PRVTJ has higher pathogenicity than the classic PRV strains.

The sensitivity and noninvasive longitudinal measurements enable the monitoring of PRV infection and clearance of a lower-dose infection of rPRVTJ-NLuc in mice (Figures 3A,B). Actually, 6-week-old mice were tended to death because of PRV infection. To obtain continuously spatial and temporal progression of PRV infection, the 7-week-old mice were used to perform in vivo imaging. In a mouse inoculated i.p. with the dose of 10^3 TCID_{50}, the infection began primarily in i.p. injection site. By 6 dpi, the bioluminescence signal decreased and appeared in the position of the spinal cord, indicating the spread of the virus to the CNS. We confirmed the infection of the spinal cord by imaging of excised organs and qPCR (Figure 3C), showing stronger bioluminescence and higher virus load in the spinal cord than in vivo image. The infection continued to be cleared and was undetectable at 7 dpi. This longitudinal measurement course could detect the dynamics of PRV by in vivo imaging and elucidate mechanisms of viral dissemination in a mouse model. It is compelling that a series of reporter viruses expressing the NLuc luciferase has the potential to assess the pathogenicity and properties of viral replication and in vivo dissemination of diverse PRV strains. Thus, this strategy should be widely applicable to any PRV isolate and will be useful to rapidly access the replication and pathogenicity characteristics of emerging PRV strains.

Although the BLI potentially offers significant advantages over other traditional virological methods, it also has a few disadvantages, e.g., the attenuation of the signal by hair and organ pigmentation, overlapping signals, and the attenuation of signals due to organ depth from the surface. Bioluminescence was not detected in the brain in any of our experiments of whole-body imaging, which is most probably due to the signal attenuation caused by the skull of mice. We confirmed the bioluminescence signal in the brain and trigeminal ganglion by imaging of excised organs. The result is consistent with detectable viral distribution in diverse tissues. Therefore, these data show that although bioluminescence is promising, precise viral tracking and the exact quantification of viral titers require combinations of these methodologies.

In summary, the recombinant PRV stably expressing NLuc luciferase is shown to be a potential tool for studying the pathogenicity mechanism of the PRV variant. We further showed that the recombinant PRV could be applied to study the infection mechanisms of PRVTJ strain by BLI. In further studies, the reporter virus will be used in the research of pathogenicity mechanism diversity of PRV variants and classic strains.

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the article.

**ETHICS STATEMENT**

All the animal experiments were approved by the Committee on the Ethics of Animal Experiments of the State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences. Five SPF BALB/c mice were bred in one box, mice were euthanized using sodium pentobarbital anesthetic before living-image and all recommended efforts were taken to minimize suffering.

**AUTHOR CONTRIBUTIONS**

YS and H-JQ designed research. YW and HW performed experiments. BW wrote the manuscript. The authors YW, HW, and BW have the equal contribution for this work and all authors reviewed the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by the National Key Research and Development Program of China (No. 2016YFD0500105), the National Natural Science Foundation of China (Nos. 31870152 and 31702279), and the Heilongjiang Natural Science Foundation (Nos. C2018067 and QC2018029).

**ACKNOWLEDGMENTS**

We thank HQ, ZJ, and employees of the Research Institute for Biological Safety Problems for their assistance in the present study.
REFERENCES

1. Verpoest S, Cay B, Favoreel H, De Regge N. Age-dependent differences in pseudorabies virus neuropathogenesis and associated cytokine expression. J Virol. 91(7):2055–16. doi: 10.1128/JVI.0258-16.

2. Sun Y, Luo Y, Wang CH, Yuan J, Li N, Song K, et al. Control of swine pseudorabies in China: opportunities and limitations. Vet Microbiol. (2016) 183:119–24. doi: 10.1016/j.vetmic.2015.12.008

3. An TQ, Peng JM, Tian ZJ, Zhao HY, Li N, Liu YM, et al. Visualizing pseudorabies virus variant in Bartha-K61-Vaccinated pigs, China. 2012. Emerg Infect Dis. (2013) 19:1749–55. doi: 10.3201/eid1911.130177

4. Gu J, Hu D, Peng T, Wang Y, Ma Z, Liu Z, et al. Epidemiological investigation of pseudorabies in Shandong Province from 2013 to 2016. Transbound Emerg Dis. (2018) 65:890–8. doi: 10.1111/tbed.12827

5. Ren JL, Wang HB, Zhou L, Guo XN, Guo X, Han J, et al. Glycoproteins C and D of PRV strain HB1201 contribute individually to the escape from bartha-K61 vaccine-induced immunity. Front Microbiol. (2020) 11:323. doi: 10.3389/fmicb.2020.00323

6. Luo Y, Li N, Cong X, Wang CH, Du M, Li L, et al. Pathogenesis and genomic characterization of a pseudorabies virus variant isolated from Bartha-K61-vaccinated swine population in China. Vet Microbiol. (2014) 174:107–15. doi: 10.1016/j.vetmic.2014.09.003

7. Hoenen T, Groseth A, Callison J, Takada A, Feldmann H. A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals. Antiviral Res. (2013) 99:207–13. doi: 10.1016/j.antiviral.2013.05.017

8. Hogue IB, Bosse JB, Engel EA, Scherer J, Hu JR, Del Rio T, et al. Fluorescent protein approaches in alpha herpesvirus research. Virus Res. (2015) 215:121–8. doi: 10.1016/j.virres.2016.02.082

9. Anindita PD, Sasaki M, Nobori H, Sato A, Carr M, Ito N, et al. Generation of recombinant rabies viruses encoding NanoLuc luciferase for antiviral activity assays. Virus Res. (2016) 215:121–8. doi: 10.1016/j.virres.2016.02.082

10. Rameix-Welti MA, Le Goffic R, Herve PL, Sourimant J, Remot A, Riffault S, et al. Visualizing the replication of respiratory syncytial virus in cells and in living mice. Nat Commun. (2015) 5:5104. doi: 10.1038/ncomms6104

11. Schoggins JW, Dorner M, Feuiller M, Imanaka N, Murphy MY, Ploss A, et al. Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro. Proc Natl Acad Sci USA. (2012) 109:14610–5. doi: 10.1073/pnas.1212379109

12. Tran V, Moser LA, Poole DS, Mehe A. Highly sensitive real-time in vivo imaging of an influenza reporter virus reveals dynamics of replication and spread. J Virol. (2013) 87:13221–32. doi: 10.1128/JVI.02381-13

13. Pan W, Dong Z, Li F, Meng W, Feng L, Niu X, et al. Visualizing influenza virus infection in living mice. Nat Commun. (2013) 4:2369. doi: 10.1038/ncomms3369

14. Karlsson EA, Meliopoulos VA, Savage C, Livingston B, Mehe A, Schultz-Cherry S. Visualizing real-time influenza virus infection, transmission and protection in ferrets. Nat Commun. (2015) 6:6378. doi: 10.1038/ncomms7378

15. Cook SH, Griffin DE. Luciferase imaging of a neurotropic viral infection in intact animals. J Virol. (2003) 77:5333–8. doi: 10.1128/JVI.77.9.5333-5338.2003

16. Luker KE, Hutchens M, Schultz T, Pekosz A, Luker GD. Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. Virology. (2003) 314:284–300. doi: 10.1016/S0042-6822(03)00424-0

17. Luker GD, Bardill JP, Prior JL, Pica CM, Piwnica-Worms D, Leib DA. Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J Virol. (2002) 76:12149–61. doi: 10.1128/JVI.76.21.12149-12161.2002

18. Burke CW, Mason JN, Surman SL, Jones BG, Dalloneau E, Hurwitz JL, et al. Illumination of parainfluenza virus infection and transmission in living animals reveals a tissue-specific dichotomy. PLoS Pathog. (2011) 7:e1002134. doi: 10.1371/journal.ppat.1002134

19. Hall MP, Unch J, Binkowski BF, Valley MP, Butler BL, Wood MG, et al. Engineered luciferase reporter from a deep sea shrimp illuminating the field of bioluminescence. Bioconjug Chem. (2016) 27:1175–87. doi: 10.1021/acs.bioconjchem.6b00112

20. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. AM J EPIDEMIOL. (1938) 27:493–7. doi: 10.1093/oxfordjournals.aje.a118408

21. Mettenleiter TC. Glycoprotein gIII deletion mutants of pseudorabies virus are impaired in virus entry. Virology. (1989) 171:623–5. doi: 10.1016/0042-6822(89)90635-1

22. Wang J, Guo R, Qiao Y, Xu M, Wang Z, Liu Y, et al. An inactivated gE-deleted pseudorabies vaccine provides complete clinical protection and reduces virus shedding against challenge by a Chinese pseudorabies variant. BMC Vet Res. (2016) 12:277. doi: 10.1186/s12917-016-0897-z

23. Meng XY, Luo Y, Liu Y, Shao L, Sun Y, Li Y, et al. A triplex real-time PCR for differential detection of classical, variant and Bartha-K61 vaccine strains of pseudorabies virus. Arch Virol. (2016) 161:2425–30. doi: 10.1007/s00705-016-2925-5

24. Tang YD, Liu JT, Fang QQ, Wang TY, Sun MX, An TX, et al. Recombinant pseudorabies virus (PRV) expressing firefly Luciferase effectively screened for CRISPR/Cas9 single guide RNAs and antiviral compounds. Viruses. (2016) 8:90. doi: 10.3390/v8040090

25. Tong W, Liu F, Zheng H, Liang C, Zhou YJ, Jiang YF, et al. Emergence of a pseudorabies virus variant with increased virulence to piglets. Vet Microbiol. (2015) 181:236–40. doi: 10.1016/j.vetmic.2015.09.021

26. Brittle EE, Reynolds AE, Enquist LW. Two modes of pseudorabies virus neuroinvasion and lethality in mice. J Virol. (2004) 78:12951–63. doi: 10.1128/JVI.78.23.12951-12963.2004

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Wang, Wu, Wang, Qi, Jin, Qiu and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.